Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 7, 2012; 18(33): 4533-4541
Published online Sep 7, 2012. doi: 10.3748/wjg.v18.i33.4533
Published online Sep 7, 2012. doi: 10.3748/wjg.v18.i33.4533
Figure 1 Time to progression (A) and overall survival (B) from the beginning of FOLFIRI for the 63 patients.
TTP: Time to progression; OS: Overall survival.
Figure 2 Subgroup analysis according to the World Health Organization performance status.
A: Time to progression (TTP) according to World Health Organization (WHO) performance status (PS). B: Overall survival (OS) according to WHO PS.
- Citation: Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine-Lefèvre L, Bonnetain F, Lévy P, Raymond E, Ruszniewski P, Louvet C, Hammel P. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol 2012; 18(33): 4533-4541
- URL: https://www.wjgnet.com/1007-9327/full/v18/i33/4533.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i33.4533